News coverage about ContraVir Pharmaceuticals (NASDAQ:CTRV) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.2723592194263 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Stock Review for Biotech’s Investors — Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics – PR Newswire (press release) (prnewswire.com)
- ContraVir Pharmaceuticals, Inc. (CTRV) stock returned -6.73% Uptick performance – The Stocks News (press release) (thestocksnews.com)
- Do Investors Feel Confident About Stock’s Future Direction? – ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) – Alpha Beta Stock (alphabetastock.com)
- Technical’s Say ContraVir Pharmaceuticals, Inc. (CTRV) stock could lead to an upward move – Nasdaq Chronicle (nasdaqchronicle.com)
Several equities analysts recently commented on the stock. Maxim Group lowered shares of ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. ValuEngine raised shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.